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Abstract
Objective: To provide guidelines for health-care providers on strategies for cervical cancer
prevention based on HPV testing and anti-HPV vaccination.
Outcomes: Overall efficacy of different preventive strategies, assessing reduction in the incidence
of invasive cervical cancer and precancerous lesions.
Evidence: Medline and the Cochrane Database were searched for articles in English on subjects
related to HPVs, HPV diagnosis, HPV anogenital lesions, cervical cancer, HPV testing, and HPV
vaccines, in order to elaborate an up-dated document. Relevant Italian Government publications
and position papers from appropriate health and family planning organizations were also reviewed.
Values: The quality of the evidence and ranking of recommendations for practice were rated using
criteria defined by SIV, which were adapted from the Canadian Task Force on Preventive Health
Care.
Introduction
This report summarizes recommendations on cervical
cancer screening and prevention strategies proposed by
experts of the Italian Society for Virology (SIV, Società Ital-
iana di Virologia) on the basis of systematic review of evi-
dence from the scientific literature and current guidelines
produced by International Societies, in view of an Euro-
pean consensus strategy for cervical cancer screening,
human papillomavirus (HPV) testing, and anti-HPV vac-
cination programs. The guidelines were discussed with
experts in the field (see acknowledgment section) and
with SIV members, and reviewed and approved by SIV Sci-
entific Committee, during the annual SIV Conference of
2008, following a specific Round table on the subject.
These recommendations recognize the diagnostic value of
HPV testing and genotyping in the management of
women with abnormal PAP test and in screening pro-
grams for prevention of cervical carcinoma and recom-
mend HPV vaccination for primary prevention of cervical
cancer. The searching strategies, the study selection criteria
and other methodologies adopted for the literature review
can be asked to the correspondig author.
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Human papillomavirus and cervical cancer
The demonstration that human papillomavirus (HPV)
infection has a pathogenetic role on cervical cancer devel-
opment and the understanding of the epidemiology of
HPV infection and its relationship with the natural history
of precancerous lesions and cervical cancer have been cru-
cial in the development of diagnostic and vaccination
strategies for prevention of one of the most common and
lethal cancers, especially in developing countries.
Epidemiology of cervical cancer and HPV infection
Epidemiological data on HPV infection and associated
disease have been reviewed in a recently published IARC
Monograph [1]. Cervical cancer is the second most com-
mon and lethal cancer in women worldwide, with esti-
mated 493,000 new cases and 274,000 deaths in 2002 [2].
More than 80% of cervical cancers and related deaths
occur in developing countries, where cervical cancer is the
most common cancer, accounting for 15% of female can-
cers, while in developed countries it accounts for only
3.6% of new cancers [2]. Cervical cancer has a relatively
low incidence in Europe (less than 15 per 100,000),
whereas its incidence is generally over 30 per 100,000 in
developing countries [3,4]. The incidence of invasive cer-
vical cancer has a peak at about 20–25 years after the peak
age for HPV infection prevalence, and the incidence of cer-
vical intraepithelial neoplasia (CIN) peaks in between [1].
According to the AIRTum (Associazione Italiana dei Reg-
istri Tumori) database, in Italy, during 1998–2002, cervi-
cal cancer represented 1.6% of all newly diagnosed
cancers among females, with an average incidence of 9.8
cases per 100,000 females per year, and represented 0.6%
of all cancer deaths among females. It has been estimated
that every year 3,418 new cervical carcinomas are diag-
nosed in Italy; as regards mortality, in 2002 there were
370 deaths due to cervical cancer, and 1,756 deaths due to
cancer of the uterus not otherwise specified [5]. Survival
rates in patients with cervical cancer vary in different
countries, ranging from 73% at 5 years in US [6] and 63%
in Europe [7] to 30.5% in sub-Saharan Africa [8]. In Italy,
at 5 years from diagnosis of cervical cancer, survival rates
range between 78% in Ferrara and 40% in Naples, with an
average national survival rate of 65% [5].
Epidemiological and experimental evidence demonstrate
that persistent infection with a carcinogenic HPV geno-
type is a necessary cause of cervical cancer and its precan-
cerous lesions, as suggested by zur Hausen in '70 [9]. Over
120 different HPV genotypes have been identified so far
and at least 40 of these HPV types infect the anogenital
mucosa [10]. Genital HPVs are designated as high-risk or
low-risk types, based on their association with cervical can-
cer [11-14]. It should be recognized that the distinction
between high-risk and low-risk HPV genotypes is contin-
uously under revision on the basis of new knowledge in
the field; therefore the definition of the oncogenicity of
some HPVs could change with time, with obvious impli-
cations on the definition of the diagnostic standards for
HPV infection, as outlined below.
High-risk HPV DNA is virtually detectable in all cervical
cancers [15]. Among high-risk or carcinogenic HPVs (cur-
rently, HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59) and probably carcinogenic HPVs (HPV types 26, 53,
66, 68, 73, 82) [4,5], HPV-16 is responsible for 60% of
cervical cancer, HPV-18 for 10%, HPV-45 and HPV-31 for
4% each, whereas HPV-33, HPV-52, and HPV-58 alto-
gether account for 2% of cervical cancer [12,16]. In high-
grade squamous intraepithelial lesions (HSIL), the most
common HPV types identified are similar to those in cer-
vical cancer, except for the under-representation of HPV-
18 and HPV-45 [16]. In low-grade squamous intraepithe-
lial lesions (LSIL), high-risk HPV DNA can be detected in
30 to 100% of cases in different studies [17]. Again, HPV-
16 is the most common type, being detected in 26% of
cases, followed by HPV-31 (12%), HPV-51 (11%), HPV-
53 and HPV-56 (10%), and many other HPV types [17].
A recent meta-analysis investigated the worldwide preva-
lence and genotype distribution of HPV DNA in cervical
samples from women with normal cytology [18]. This
meta-analysis estimated the overall HPV prevalence in
women with normal cytology was 10.4% (95% confi-
dence interval [CI], 10.2–10.7%). The prevalence was rel-
atively high in Africa, Central America and Mexico (about
20 to 30%) and lower in northern America, Europe, and
Asia (about 8 to 11%). In all world regions, HPV preva-
lence was highest in women younger than 35 years of age,
decreasing in women of older age [18]. In Africa, the
Americas, and Europe, a second peak of HPV prevalence
was observed in women of older age [18]. Overall, the
most common HPV types were HPV-16, HPV-18, HPV-31,
HPV-58, and HPV-52, while the most common types in
southern Europe were HPV-16, HPV-66, HPV-45, HPV-
31, and HPV-42 [18].
In the Italian population, the prevalence of high-risk HPV
in women aged 25–70 years has been reported to be about
9%, and HPV-16 was the most common genotype, being
detected in 30–60% of HPV-positive women, followed by
HPV-66, HPV-45, HPV-31, and HPV-53 [19,20]. HPV gen-
otyping by restriction fragment length polymorphism
analysis and direct sequencing showed that, in HSIL,
HPV-16 and HPV-31 were the most commonly detected
types, followed by HPV-67, HP-87, HPV-61, and HPV-58,
while HPV-16, HPV-31, HPV-66, HPV-53, HPV-52, and
HPV-56 were the most frequent types in LSIL [21]. By con-
trast, low-risk HPV-6 and HPV-11 were responsible for
about 90% of genital warts [22], whereas the other low-
risk HPV types were less frequently associated with ano-Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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genital lesions. Data at recruitment from the New Tech-
nologies for Cervical Cancer Screening (NTCC)
randomized trial, which is ongoing in Italy and includes
women attending routine cervical screening programs,
showed the rates of high-risk HPV positivity were 13.1%
for women aged 25–34 and 5.8% for women aged 35–60,
without a second peak of HPV prevalence [23]. In younger
women aged 18 to 24, the prevalence of high-risk HPV
DNA detection is 17.4% and HPV-16 was the most fre-
quent type, followed by HPV-53, HPV-84, HPV-42, HPV-
62, HPV-66, and HPV-89 [24]. A higher prevalence has
been reported in a Danish population-based study [25],
which showed that about 40% and 45% of women aged
15–19 and 20–24 years, respectively, were infected with
high-risk HPV types. HPV-16 was the most common HPV
type, followed by HPV-31, HPV-52, and HPV-51 [25].
Like in the Italian population, the prevalence of infection
markedly decreased with age, without significant second
prevalence peak [25]. The EDITH (Etude de la Distribu-
tion des Types d'HPV en France) study investigated the
prevalence and distribution of HPV types in France. The
results of this study showed that HPV DNA could be
detected in 98% of LSIL smears, in 98% of high-grade cer-
vical intraepithelial neoplasia (CIN2/3), and in 97% of
invasive cancers [26-28]. In LSIL, the most prevalent gen-
otypes were HPV-66, HPV-16, HPV-53, HPV-51 and HPV-
52 [26]; in CIN2/3, HPV-16 was by far the most prevalent
genotype (62%), followed by HPV-31, HPV-33, HPV-52,
HPV-51, and HPV-58 [27], while the most prevalent gen-
otypes in invasive cervical cancer were HPV-16 (73%) and
HPV-18 (19%), followed by HPV-31 (7%), HPV-33, HPV-
68, HPV-45, HPV-52, and HPV-58 (4.1-2.3%) [28]. While
HPV-16 was the most prevalent type in both squamous
cell carcinoma (74%) and adenocarcinoma (64%), HPV-
18 was more prevalent in adenocarcinoma (37%) com-
pared to squamous cell carcinoma (16%) [28].
Besides cervical cancer, HPV infection is associated with
over 70% of cases of anal carcinoma and squamous
oropharyngeal carcinoma, with 50% of vulvar, vaginal,
and penile cancer, and, in immunocompromised
patients, with about 90% of cutaneous squamous cell can-
cer [12,29,30]. In Italy, high-risk HPV DNA, mainly HPV-
16, was detected in 46% of cases of penile carcinoma [31].
Pathogenesis
Several basic experimental studies have clarified the
mechanisms of HPV oncogenesis [29,32]. In its life cycle,
HPV requires infection of epidermal or mucosal epithelial
cells of the basal layer, that are still able to proliferate,
most probably through wounds or abrasions. In basal
layer cells, viral gene expression is largely suppressed,
although the limited expression of the early viral genes E1,
E2, E5, and especially E6 and E7, results in enhanced pro-
liferation of the infected cells and in their lateral expan-
sion [33]. Following entry into the suprabasal layers,
expression of the late viral genes E4, L1, and L2 is initi-
ated; the circular viral genome is then replicated and struc-
tural proteins form. In the upper layers of the epidermis or
mucosa, complete viral particles are assembled and
released [33]. The HPV E1 and E2 proteins are involved in
replication and segregation of episomal viral genome
[34]; the E2 protein also acts as a transcriptional activator
of viral promoters through its ability to bind to specific
sequences within the regulatory sequences of HPV
genome, known as long control region (LCR) [35]. How-
ever, in some cases, E2 may also inhibit viral gene tran-
scription: in genital tract-associated high-risk HPV, E2
protein has been demonstrated to suppress E6 and E7
expression probably through steric interference with the
binding of positively acting cellular transcription factors
in the LCR [36]. HPV E4 function is probably to aid the
virus in its egress from the cell [37]. E5 seems to be impor-
tant in the early course of infection. It probably stimulates
cell growth by forming a complex with the epidermal
growth factor receptor or a subunit of the vacuolar
ATPase, thus inhibiting the acidification of endosomes
and growth factor receptor recycling [38,39]. However,
since the E5 gene is not expressed in most HPV-positive
cancers, E5 does not seem to be obligatory in late events
of HPV-mediated carcinogenesis [33]. A more significant
role for malignant transformation can be assigned to the
E6 and E7 genes and their respective proteins. They are
consistently expressed in malignant tissue, and inhibiting
their expression blocks the malignant phenotype of cervi-
cal cancer cells [40]. They are independently able to
immortalize various human cell types in tissue culture,
and show synergistic activity when they are expressed
together. Interestingly, in high risk HPVs, E6 and E7 pro-
tein are translated together from a polycistronic mRNA
[33].
The E7 protein encoded by high-risk HPV is a small mul-
tifunctional nuclear protein that binds zinc, is phosphor-
ylated by casein kinase II, and shares structural similarities
with oncoproteins of other DNA tumor viruses [41]. The
most significant cellular targets of E7 are the retinoblast-
oma (Rb) tumor suppressor protein and its functionally
related proteins, p107 and p130, especially in their hypo-
phosphorylated active forms, which are able to inhibit cell
cycle progression by binding and repressing the activity of
E2F cellular transcription factors [42]. Binding with high-
risk E7 results in pRb proteasomal degradation, but this
event is not sufficient to account for E7 transforming func-
tions [43]. Indeed, E7 has additional cellular targets, such
as the cyclin-dependent kinase inhibitors p27kip1  and
p21cip1, which are inactivated [44-46], and causes
genomic instability leading to chromosomal abnormali-
ties and aneuoploidy [47].Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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The first transforming activity identified for the high-risk
HPV E6 proteins was the ability to mediate p53 degrada-
tion through the ubiquitin proteolysis pathway [48], a
property not possessed by the low-risk HPV E6 proteins.
E6 first associates with the cellular ubiquitin ligase protein
termed  E6-associated protein (E6AP), then the E6-E6AP
complex binds to p53, stimulating its ubiquitination and
degradation [49]. In targeting p53, the high-risk HPV E6
proteins inhibit DNA damage and oncogene-mediated
cell death signals. E6 from high-risk HPV also interacts
with several other cellular proteins involved in DNA rep-
lication, signal transduction (NFX1), activation of telom-
erase (Myc), cell proliferation (PDZ motif-containing
proteins), and inhibition of apoptosis (Bak, CBP/p300)
[33].
Invasive cervical cancers and precancerous lesions associ-
ated with high-risk HPV infection are characterized by
integration of HPV DNA in cellular chromosomes. Viral
DNA integration is associated with deletion of large seg-
ments of viral genome, but with the presence of intact E6
and E7, and with transcription of sequence downstream
from the integrated LCR [50]. Disruption of the viral E1
and E2 genes, as well as of downstream viral sequences,
may permit higher levels of E6 and E7 transcription,
whose RNA are stabilized following fusion with down-
stream cellular sequences [51]. Persistent expression of E6
and E7 appears to be necessary to maintain the malignant
phenotype and to favour the occurrence of cellular genetic
and epigenetic events, which are important for cancer pro-
gression [52].
Screening for cervical cancer and diagnosis of 
HPV infection
Screening programs for cervical cancer prevention derive
from knowledge on the natural history of cervical cancer
and its precancerous lesions and the role of HPV infection
in cancer development. These programs, which vary
widely by country, include screening tests for early detec-
tion of cancer, as well as management strategies for treat-
ment and post-treatment follow-up. Several international
and national scientific societies have drawn guidelines on
cervical cancer screening and prevention, which are sum-
marized in Table 1. All these guidelines emphasize the
utility to incorporate HPV testing as an adjunct to cervical
cytology in cervical cancer screening programs in women
aged ≥ 30 years and for management of women with an
abnormal Pap test.
Guidelines of the American Cancer Society [53,54] recom-
mend that screening should begin approximately 3 years
after a woman starts having vaginal intercourse, but no
later than age 21 years. Screening should be done every
year with conventional Pap tests or every 2 years using liq-
uid-based cytology testing. At or after age 30 years, women
who have had 3 normal test results in a row may get
screened every 2 to 3 years with cervical cytology alone, or
every 3 years with cytology test plus high-risk HPV DNA
testing (HPV test). Women aged ≥ 70 years who have had
3 or more normal Pap tests and no abnormal Pap tests in
the last 10 years and women who have had total hysterec-
tomy may choose to stop cervical cancer screening. Special
recommendations are given to at-risk categories (i.e., his-
tory of cervical cancer, in utero exposure to diethyl-
stilbestrol, immunosuppression). Similar guidelines have
been proposed by the American College of Obstetricians
and Gynecologists in 2003 http://www.acog.org, by the
U.S. Preventive Services Task Force in 2003 http://
www.preventiveservices.ahrq.gov, and, more recently, in
2006, by the American Society for Colposcopy and Cervi-
cal Pathology [55,56].
In European Union member states, screening programs
for cervical cancer prevention are organized according to
the European Council [57] and the European Guidelines
[58], which recommend to set up cancer screening as a
population-based public health programme, with identi-
fication and personal invitation of each woman in the eli-
gible target population, and to discourage opportunistic
screening. According to these guidelines, cervical cytology
is the currently recommended standard test for cervical
cancer screening, which should start in the age range 20–
30 years. Screening is recommended to be continued at 3–
5-year intervals until the age of 60–65. In older women,
who have had three or more consecutive previous recent
normal cytology results, stopping screening is considered
appropriate, while special attention has to be paid to
those who have never attended screening. While waiting
for the results of ongoing longitudinal trials before recom-
mending HPV screening, HPV DNA testing is proposed in:
1) primary screening for oncogenic HPV types alone or in
combination with cytology; 2) triage of women with
equivocal cytological results; 3) follow-up of women
treated for CIN to predict success or failure of treatment.
Referral for colposcopy is recommended for women with
a high-grade cytological lesion (ASC-H and HSIL or
higher), a repeated low-grade lesion, or with an equivocal
cytology result and a positive HPV test. Management
options in case of atypical squamous cells of undeter-
mined significance (ASC-US) include reflex HPV DNA
testing (preferred option when HPV testing is available),
repeating the Pap smear after 6 to 12 months, or referral
for colposcopy and cervical biopsy (when poor follow-up
compliance is suspected or when explicit risk factors are
present). Repeat cytology or referral for colposcopy (pre-
ferred option) are considered acceptable options for ini-
tial management of LSIL, while HPV testing is considered
not sufficiently selective. The guidelines of the Italian
Ministry of Health for the cervical cancer screening suggest
performing a Pap test every three years in women agedInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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25–64, as first level of screening, followed by specific rec-
ommendations for women with abnormal cytology [59].
In particular, referral for colposcopy is recommended in
the case of ASC-H and HSIL or higher at Pap test, while the
following management options are acceptable in the case
of ASC-US: triage with reflex HPV DNA test (and referral
to colposcopy if HPV DNA test is positive), immediate
referral to colposcopy, or repeat Pap cytology after 6
months. Referral to colposcopy is the preferred manage-
ment strategy for LSIL, although triage with HPV testing is
also acceptable [59].
Cytology testing
Screening programs based on cytology testing led to the
reduction of the incidence of cervical cancer and cancer-
related mortality of about 70–80% in many industrialized
countries [1].
The efficacy of conventional cytological screening for cer-
vical cancer has never been investigated in randomised
clinical trials, but evidence of its effectiveness derives from
observational studies. Diagnostic performance of cervical
cytology has been evaluated by several studies in the liter-
ature, whose results have been reviewed in recent meta-
analyses. These studies have demonstrated that a single
cytology test has a sensitivity of about 50% for identifying
women with high-grade precancerous lesions or invasive
cervical carcinoma (i.e., cervical intraepithelial neoplasia
type 2 or higher, CIN2+) [60-63]. In particular, a recent
meta-analysis on 8 cervical cancer screening studies done
in North American and European countries with estab-
lished cytology-based screening activities, including over
60,000 women who were tested for both HPV DNA and
cytology, found that the overall relative sensitivity of
cytology for CIN2+ was 53.0% (95% CI, 48.6%–57.4%),
Table 1: European and US guidelines on cervical cancer screening and prevention.
European 
guidelines for 
quality assurance in 
cervical cancer 
screening; 2007 [58]
ACS (American 
Cancer Society); 
2007 [53,54]
ACOG (American 
College of 
Obstetricians & 
Gynecologists); 
2003 http://
www.acog.org
ASCCP (American 
Society for 
Colposcopy & 
Cervical 
Pathology); 2006 
[55,56]
US Preventive 
Service Task Force; 
2003 http://
www.preventiveservic
es.ahrq.gov
Initiation of screening 
with Pap cytology
20–30 yr about 3 yr after the 
onset of sexual 
activity but no later 
than age 21 yr
about 3 yr after the 
onset of sexual 
activity but no later 
than age 21 yr
NR within 3 yr of onset of 
sexual activity or age 
21 yr, whichever 
comes first
Use of HPV testing in 
screening programs
Not recommended 
while waiting for the 
results of randomized 
controlled trials.
With cytology in 
women ≥ 30 yr
With cytology in 
women ≥ 30 yr
Insufficient evidence
Screening intervals
- conventional Pap 
test
3–5 yr Annually; every 2–3 yr 
for women aged ≥ 30 
yr with 3 consecutive 
negative cytology 
tests.
Annually; every 2–3 yr 
for women aged ≥ 30 
yr with 3 consecutive 
negative cytology 
tests.
NR At least every 3 yr
- if HPV testing used NR Every 3 yr if HPV 
negative and cytology 
negative.
Every 3 yr if HPV 
negative and cytology 
negative.
NR Insufficient evidence
Discontinuation of 
screening
60–65 yr with ≥ 3 
recent consecutive 
negative tests.
Women aged ≥ 70 yr 
with ≥ 3 recent 
consecutive negative 
tests and no abnormal 
tests in prior 10 yr.
Inconclusive evidence 
to establish upper age 
limit.
NR Women aged ≥ 65 yr 
with negative tests, 
who are not 
otherwise at high risk 
for cervical cancer.
Management of 
abnormal cervical 
cancer screening test
- ASC-US
- ASC-H
- LSIL
- HSIL
ASC-US: reflex HPV 
testing;
LSIL: repeat cytology 
or colposcopy;
ASC-H: colposcopy;
HSIL: colposcopy and 
biopsy.
NR NR ASC-US: HPV testing, 
or repeat cytology, or 
colposcopy in women 
≥ 20 yr;
ASC-H: colposcopy
LSIL: colposcopy
HSIL: immediate loop 
electrosurgical 
excision or 
colposcopy with 
endocervical 
assessment.
NR
NR: not reported.Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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by using ASC-US as cut-off for a positive result [62]. More-
over, sensitivity of cytology varied considerably among
studies, ranging from 18.6% to 76.7% [62]. In fact, cytol-
ogy testing has been shown to have poor inter-laboratory
and inter-operator reproducibility [64]. The meta-analysis
also showed the sensitivity of cytology testing increases
with patient's age and is significantly higher in women
over the age of 50 than in younger women (79.3% vs.
59.6%, respectively). The overall specificity of cytology for
CIN2+ is very high (96.3%; 95% CI, 96.1–96.5%), and
this is an important requisite for a screening test, and is
even higher in women aged ≥ 35 years than in younger
women (97.1% vs. 95.9%, respectively) [62]. More recent
meta-analyses involving more European/North American
studies yielded a pooled sensitivity of cytology at cut-off
ASCUS+ for finding CIN2+ of 70% (95% CI: 60–83%).
After omission of three German studies, which reported
very low sensitivity data, the pooled sensitivity increased
to 78% (95% CI: 69–87%) [63,65].
Liquid-based cytology has been more recently introduced
and is now widely used for primary screening of cervical
cancer. It has the advantage of allowing automation, faster
reading times, and to be used for adjunctive testing,
including HPV testing. It has been suggested to be more
sensitive than conventional cytology, but this feature has
been rebutted by recent randomized studies, which com-
pared the accuracy of liquid-based cytology with conven-
tional cytology for primary screening of cervical
carcinoma [66,67]. In these studies, liquid-based cytology
showed no significant difference in sensitivity to conven-
tional cytology for detection of CIN2+, besides a lower
positive predictive value (PPV) due to a higher number of
positive results. It showed however the advantage of a
reduction of unsatisfactory smears [67].
HPV test
Currently used molecular tests for the detection of nucleic
acids of high-risk HPV in clinical specimens are based on
signal-amplification and hybridization methods, such as
the Hybrid Capture® II assay (HC2, Diagene Corp., Gaiths-
burg, Maryland, USA), or on target amplification, like the
polymerase chain reaction (PCR)-based Amplicor® HPV
test (Roche Molecular Diagnostics, Switzerland) or other
PCR-based assays. The HC2 test, to date, is the only com-
mercially available HPV DNA detection test that is
approved by the FDA for cervical cancer screening in com-
bination with cytology after the age of 30 years. The HC2
test is a nucleic acid hybridization assay with signal ampli-
fication for the qualitative detection of HPV DNA of 13
high-risk types in cervical specimens. The HC2 assay can-
not identify the specific HPV type, since detection is per-
formed with a combined probe mix, and provides a semi-
quantitative estimate of HPV DNA load. PCR-based assays
use consensus or general primers, such as the GP5+/6+
PCR system, the Roche Amplicor®  system, the PGMY
primer set, and the SPF10 primer set, to amplify a broad
spectrum of HPV types. These primers target the L1 gene
in a conserved region amongst HPVs. Subsequent to
amplification of HPV DNA, detection of high-risk HPV
types is performed by hybridization with probes specific
for high-risk HPVs. HPV genotyping is performed by type-
specific PCR or by amplification of HPV DNA by using
consensus or general primers, followed by sequencing,
restriction fragment length polymorphism analysis, or
reverse hybridization of the amplicon to multiple oligo-
nucleotide probes corresponding to high-risk and low-
risk HPVs. Reverse hybridization assays, such as the linear
array by Roche Diagnostics, the line probe assay by Inno-
genetics NV (Belgium), microchips by Biomedlab Co.
(Korea) and by other companies, Multiplexed Luminex
Assay (Multimetrix, Germany), etc., are able to identify
co-infections by different HPV types, at variance with
sequencing-based assays, which have high accuracy in the
definition of HPV types but poor sensitivity in co-infec-
tions.
Applications of HPV testing in cervical cancer 
screening programs
Using HPV DNA test for triage of abnormal Pap test
HPV testing has been introduced in programs for cervical
cancer prevention after numerous studies had demon-
strated that detection of high-risk HPVs has a higher sen-
sitivity than cytology testing in predicting high-grade
cervical precancerous lesions or invasive cervical carci-
noma. A meta-analysis on the use of HPV testing to man-
age women with ASC-US showed that HPV testing has a
greater accuracy than repeat cervical cytology [61]. In fact,
the overall sensitivity and specificity of HPV testing were
84.4% and 72.9%, respectively, vs. 57.6% and 81.8% of
Pap-test, by using ASC-US as cut-off for a positive result;
by using LSIL as cut-off, Pap test sensitivity was reduced to
45.7%, whereas specificity increased to 89.1% [61].
Among the studies included in the meta-analysis, there
was the large ALTS (ASCUS Low SIL Triage Study), a con-
trolled clinical trial, which enrolled 3,488 women, rand-
omized into three intervention groups: immediate
colposcopy, repeated liquid-based cytology, or HPV test-
ing. This trial, as confirmed also by other similar studies,
demonstrated that HPV testing for ASC-US triage had a
significantly higher sensitivity and similar specificity for
CIN3+ than repeat cytology [68,69]. Based on these
results, both the American Society for Colposcopy and
Cervical Pathology (ASCCP) [55,56] and the European
Guidelines [58] currently recommend HPV testing using
validated HPV assays as an acceptable method for manag-
ing women over the age of 20 years with ASC-US. Accord-
ing to ASCCP guidelines, women with ASC-US who are
HPV DNA negative can be followed up with repeat cyto-
logical testing at 12 months, whereas those who are HPVInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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DNA positive should be referred for colposcopic evalua-
tion. If CIN is not identified, repeat HPV testing at 12
months is recommended. However, women with ASC-US
who are HPV DNA negative have a very low probability of
having CIN2+, lower than the general population with
negative cytology and unknown HPV status, who is actu-
ally referred to three years. So, a more conservative man-
agement strategy than ASCCP recommendations could be
appropriate.
HPV testing has not been demonstrated to be a useful
management option for women with a cytological result
of LSIL. In fact, a meta-analysis of published studies dem-
onstrated HPV triage of LSIL had no significantly higher
sensitivity but lower specificity than repeat cytology in the
detection of high-grade CIN [70]. In particular, the ALTS
study found that over 80% of women with LSIL were
HPV-positive, whereas the prevalence of CIN2+ was con-
siderably lower [71]. Nevertheless, reflex HPV testing may
be cost effective in older women with LSIL, due to consid-
erably lower prevalence of HPV infection. In this regard,
data from the randomized Italian study New Technolo-
gies for Cervical Cancer Screening (NTCC), which com-
pared accuracy of cytology testing vs. HPV DNA testing,
specificity of HPV testing for triage of LSIL was higher in
women aged over 35 years than in younger women, since
the proportion of HPV positive women was much lower
in women aged 35–60 years than in those aged 25–34
years (42% vs. 72%) [72]. So, HPV triage could be appro-
priate also for LSIL in women over 35 years, in order to
reduce colposcopy burden and to increase the positive
predictive value of the colposcopy referral.
Using HPV DNA test for follow-up after treatment of 
cervical dysplasia
Several studies demonstrated that HPV testing, performed
at 4–6 months intervals following ablative therapy for
high-grade lesions (CIN2–3), has a higher sensitivity and
specificity than cytology in detecting residual disease or
recurrence [73-75]. In a meta-analysis of 11 studies evalu-
ating HPV DNA testing in monitoring women after treat-
ment of CIN3, the negative predictive value of HPV testing
for recurrent/residual disease was 98%, whereas the nega-
tive predictive value of cytology was 93% [76]. Overall,
the sensitivity of HPV testing for identifying recurrent/per-
sistent CIN reaches 90% by 6 months after treatment and
remains high for at least 24 months, at variance with cyto-
logical follow-up, which has a sensitivity of approxi-
mately 70%. These findings were confirmed in an updated
meta-analysis, which showed HPV testing has a signifi-
cantly higher sensitivity (ratio: 1.27; 95% CI: 1.06–1.51)
and not-significantly lower specificity (ratio: 0.94; 95%
CI: 0.87–1.01) than follow-up cytology in the prediction
of residual/recurrent CIN [65].
HPV testing at 6–12 months for post treatment manage-
ment of CIN2,3 is recommended by current guidelines of
the American Society for Colposcopy and Cervical Pathol-
ogy [56], whereas European Guidelines, while waiting for
further data from clinical trials, recommend double test-
ing with cytology and an HPV test at 6 months post treat-
ment [58].
Using HPV DNA test for cervical cancer screening
The potential role of HPV testing as a stand-alone test or
in conjunction with cytology in cervical cancer screening
has been investigated in several studies [reviewed in
[62,65,77]]. Unfortunately, these studies were performed
with different techniques and sometimes gave conflicting
results.
A meta-analysis including 25 non-randomized clinical tri-
als, which compared the performance of cytology vs. HPV
test in screening programs for prediction of CIN2+ [63],
showed the overall sensitivity of HPV test was 90%, when
the HC2 assay was used, and 80.9%, when PCR with con-
sensus primers was employed; overall specificity was
higher in PCR-based tests than in HC2, being 94.7% and
86.5%, respectively. The accuracy of cytology testing was
lower than HPV testing: in fact, with ASC-US as a cut-off,
sensitivity was 72.7% and specificity 91.9%. In women
aged over 30 yr, the overall sensitivity of the HC2 assay
was 94.8% and specificity 86% [63].
Likewise, the meta-analysis by Cuzick et al. [62], which
included only studies from European and North Ameri-
can countries, where screening programs are well imple-
mented, showed the overall sensitivity and specificity of
HPV testing were 96.1% and 90.7%, respectively, whereas
the overall sensitivity and specificity of cytology testing
were 53.0% and 96.3%, respectively. Moreover, at vari-
ance with cytology testing, sensitivity of the HPV test did
not vary among the different Centres and was very high
both in young women and in those over 50 years of age.
Among the studies included in this meta-analysis, there
was the HART (HPV in Addition to Routine Testing) trial,
a multicentric screening protocol which enrolled over
10,000 women aged 30–60 years attending for routine
screening. In this study, women with borderline cytology
or negative cytology but positive HPV test were rand-
omized to immediate colposcopy or follow-up with
repeat HPV test, cytology testing, or colposcopy at 12
months [78]. The HART study confirmed HPV testing is
more sensitive than borderline or worse cytology (97.1%,
95% CI 91.2–99.1%, vs. 76.6%, 95% CI 65.1–85.1%) but
less specific (93.3%, 95% CI 92.7–93.9%, vs. 95.8%, 95%
CI 95.4–96.2%) for detecting CIN2+ [78]. Comparison of
management strategies for borderline cytology and for
positive HPV test with negative cytology results at baseline
showed that surveillance at 12 months was as effective asInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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immediate colposcopy [78]. Interestingly, no CIN2+ were
detected in women with a positive HPV test at baseline
but negative at follow-up nor in those with an initial neg-
ative HPV test and borderline or mild cytology [78]. Based
on these results, it was suggested that HPV test could be
used as a screening test in women over 30 years of age
with cytology triage of HPV-positive results. In case of nor-
mal or borderline cytology, repeat HPV testing after 12
months was indicated [78].
Randomized longitudinal studies [79], which have been
conducted more recently, were not included in the meta-
analyses. One of these studies is the NTCC study, an ongo-
ing clinical trial in Italy nested in the routine activity of
organized screening programmes, which enrolled approx-
imately 95000 women, who were randomly assigned to
conventional cytology or to an experimental arm that fol-
lowed two phases depending on the period of recruitment
[23]. During the phase 1 of recruitment, women were ran-
domly assigned to the conventional arm for screening by
conventional cytology or to the experimental arm, which
used both HPV DNA testing with HC2 and liquid-based
cytology. HPV-positive women were managed differently
according to age. Among women aged 35–60 years, those
who had a cytological abnormality or were HPV-positive
were referred to colposcopy. Among women aged 25–34
years, all women with abnormal cytology were referred for
colposcopy but those who were HPV-positive with nor-
mal cytology were retested after 1 year and referred for col-
poscopy only if HPV positivity persisted or if cytology
became ASC-US+. During the phase 2 of recruitment,
women were randomly assigned to conventional cytology
with referral for colposcopy if cytology indicated ASC-US+
or to HPV DNA testing alone with referral for colposcopy
if the test was positive [23]. Results at recruitment showed
that the screening method in the experimental arm was
more sensitive than conventional cytology in women
aged 35–60 years [80]. In particular, referral based on
HPV testing with HC2 at a high cut-off value of 2 pg/mL
showed a higher sensitivity than conventional cytology
for detection of CIN2+ (relative sensitivity, 1.41%; 95%
CI, 0.98–2.01), but a lower positive predictive value (PPV;
relative PPV, 0.75; 95% CI, 0.45–1.27). The use of the 2
pg/mL cut-off led to a higher PPV than the 1 pg/mL cut-off
[80]. Adding liquid-based cytology improved sensitivity
only marginally but increased false positives [80]. In
women younger than 35 years, HPV testing alone as pri-
mary test, with triage of HPV-positive women by cytology,
appeared to be the best approach, since the use of liquid-
based cytology did not increased the sensitivity for CIN2+
detection and had a significantly lower PPV as compared
with conventional cytology. Moreover, addition of liquid-
based cytology as a primary screening test to HPV testing
had a negligible effect on sensitivity but strongly reduced
PPV compared with HPV testing only [81]. The use of
more restricted referral criteria (i.e., cut-off of 2 pg/mL and
positive results at repeat HPV testing) was predicted to
increase PPV to that obtained with conventional cytology
[81].
Results from the second recruitment phase of the NTCC
study showed that, in women aged 35–60 years, HPV test-
ing alone with a cut-off of 2 pg/mL achieved a substantial
gain in sensitivity over conventional cytology with only a
small reduction in PPV (relative sensitivity, 1.81; 95% CI,
1.20–2.72; relative PPV, 0.99; 95% CI, 0.67–1.46) [23],
confirming the results of the first phase of the study [80].
In women aged 25–34 years, direct referral to colposcopy
after a positive HPV test led to detection of a significantly
greater number of CIN2+ and CIN3+ lesions than in the
first phase of the study [23]. The increased sensitivity of
HPV testing for CIN2+ in the second phase of the study as
compared with the first was suggested to be related to a
high rate of high-grade lesions in young women, which
spontaneously regress [23]. So, in order to avoid over-
treatment, it was suggested that HPV-positive women
aged 25–34 years should be referred to colposcopy only if
cytology is also abnormal or if infection persists after 1
year [23]. In older women, high-grade lesions are less
likely to regress [78,80], therefore a more aggressive man-
agement strategy for HPV-positive results appears to be
justified. On the other hand, referral to colposcopy of
women with abnormal cytological findings (ASC-US+)
but a negative HPV test may led to a high-rate of false pos-
itive CIN2+ results and, as a consequence, to overtreat-
ment [82].
Persistence of the additional lesions detected at baseline
by HPV testing in older women was also suggested by the
recently published results from two longitudinal rand-
omized controlled trials, that included only women at
least 30 [83] or 32 [84] years of age. One of the trials is the
Population Based Screening Study Amsterdam (POBAS-
CAM), which aims to assess whether primary HPV DNA
testing is more effective than cytological testing in the set-
ting of a regular screening programme. This study enrolled
women aged 30–56 years and attending the regular cervi-
cal cancer screening programme in the Netherlands.
Women were randomly assigned to the intervention
group (screening with HPV DNA testing combined with
Pap test) or control group (Pap test only, HPV DNA test
results blinded). After 5 years, combined cytological and
HPV DNA testing were done in both groups and follow-
up data for ≥ 6.5 years were available for 17,155 women.
Management strategies were more conservative than in
the NTCC study. In fact, women with HSIL or worse were
immediately referred to colposcopy, irrespective of the
HPV result, whereas repeat testing after 6 and 18 months
was advised to women with normal cytology but positive
HPV test and to those with ASC-US, ASC-H, or LSIL.Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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Women with repeat positive cytology and HPV test results
were referred to colposcopy [83]. In this study, detection
of HPV DNA was done by GP5+/6+ PCR followed by
enzyme immunoassay detection of 14 high-risk HPV
types with a cocktail of oligonucleotide probes. The other
trial was conducted in Sweden and enrolled 12,527
women aged 32 to 38 years, who, like in the POBASCAM
study, were randomized to have an HPV test plus Pap test
or a Pap test alone [84]. In this study, HPV test was based
on GP5+/6+ PCR followed by reverse dot blot hybridiza-
tion to identify 14 high-risk HPVs. Women with a positive
HPV test and a normal Pap test were offered a second HPV
test at least 1 year later, and those who were found to be
infected with the same high-risk HPV type were offered
colposcopy with cervical biopsy. To avoid ascertainment
bias, a similar number of Pap smears and colposcopy with
biopsies were performed in randomly selected women in
the control group. All women were followed for a mean of
4.1 years with annual Pap smears and HPV tests, with col-
poscopy in cases of persistent high-risk HPV infection
[84]. Both studies showed that a significantly higher
number of CIN2+ or CIN3+ lesions were detected at base-
line in the intervention group than in the control group,
whereas the number of lesions detected in the subsequent
follow-up visit, when both HPV test and cytology were
done, was significantly lower in the intervention group
than in the control group [83,84], thus indicating that
implementation of HPV DNA testing in cervical cancer
screening leads to earlier detection of high-grade lesions,
thus allowing longer screening intervals. In the Dutch
study, the 5-year cumulative risk of CIN3+ was 0.1%
(95% CI, 0.1–0.2%) after a combined negative HPV DNA
and cytological result at baseline and 0.8% (95% CI, 0.6–
1.0%) after a negative cytology at baseline, but without
HPV testing [83]. After a negative HPV test at baseline, the
5-year cumulative risk of CIN3+ was estimated as 0.2%
(95% CI, 0.1–0.3%) [83]. Likewise, in a longitudinal
cohort study which enrolled over 20,000 women in Port-
land who underwent simultaneous screening with a Pap
test and HPV testing with HC2, the 5-year cumulative risk
of CIN3, was 4.4% for women who were HPV-positive at
baseline, but only 0.24% among women with a negative
HPV test and 0.16% when both the HPV test and Pap
smear were negative [85].
A direct comparison between Pap test and HPV test (by
using the HC2 assay) as stand alone tests for cervical can-
cer screening was evaluated in a recent randomized trial in
Canada, involving 10,154 women aged 30–69 years [86].
Both tests were performed on all women in a randomly
assigned order but, to the aim of the study, only one first
test was considered for statistical evaluation. Women with
abnormal Pap test results or a positive HPV test at 1 pg/mL
cut-off underwent colposcopy and biopsy, as a random
sample of women with negative tests. Results at baseline
testing showed sensitivity of HPV testing for CIN2 or
CIN3 was 94.6% (95% CI, 84.2–100%), significantly
higher than sensitivity of Pap test, which was 55.4% (95%
CI, 33.6–77.2%). HPV test specificity was 94.1% (95% CI,
93.4–94.8%) and 96.8% for Pap testing (95% CI, 96.3–
97.3%) [86].
Recommendations on the use of HPV testing in cervical
cancer screening programs (grading of recommenda-
tions is reported in Table 2)
￿ HPV testing is recommended for ASC-US triage since
HPV test is more sensitive than repeat cytology for detec-
tion of CIN2+ (IA).
￿ HPV testing is, in general, not a management option in
case of LSIL (ID), even if it may be cost effective in older
women with LSIL (IB). Local assess is needed to identify a
good triage test for women with LSIL (research need).
Table 2: Key to evidence statements and grading recommendations defined by SIV.*
Strength of Recommendation
A. Good evidence for efficacy and substantial clinical benefit support recommendation for use.
B. Moderate evidence for efficacy or only limited clinical benefit supports recommendation for use.
C. Evidence for efficacy is conflicting and does not allow supporting a recommendation for or against use, but recommendations may be made on 
other grounds.
D. Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use.
E. Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use.
I. There is insufficient evidence (in quality and quantity) to make a recommendation; however, other factors may influence decision-making.
Quality of Evidence
I. Evidence from at least 1 randomized, controlled trial.
II. Evidence from at least 1 clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than 1 
centre) or from multiple time-series studies or dramatic results from uncontrolled experiments.
III. Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
*: Quality of evidence and grading of recommendations were defined and approved by SIV; they were adapted from The Evaluation of Evidence and 
the Classification of Recommendations criteria described in The Canadian Task Force on Preventive Health Care.Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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￿ HPV testing, alone or in combination with cytology, is
recommended for follow-up after treatment of high-grade
cervical lesions, since it is more accurate than repeat cytol-
ogy in diagnosing residual disease or relapse (IA).
￿ HPV testing, both based on hybridization (HC2) and
PCR amplification with detection of high-risk HPVs, has
been widely used in women aged >30 years in addition to
Pap cytology because of the high NPV of a combined neg-
ative test (I). Women with normal Pap test result and neg-
ative HPV test have a very low risk to develop cervical
cancer and should not perform the subsequent follow-up
visit earlier than 5 years (IA). However, combination of
HPV testing and Pap cytology is not a cost-effective strat-
egy (I), so, strategies based on HPV testing as a stand alone
test should be preferred in women aged >30 years (IA).
￿ Follow-up with HPV testing or repeat cytology at 12
months is recommended for cytology-negative, HPV-pos-
itive women aged ≥ 30 years (IA). Women who are persist-
ently HPV-positive on repeat testing should undergo
colposcopy, whereas those who are negative on both tests
may be rescreened in 5 years (IA).
￿ Using the HPV test in screening programs leads to earlier
detection of CIN2+ and CIN3+ and reduction of the
number of high-grade lesions detected at subsequent fol-
low-up in women aged ≥ 30 years (I), thus allowing
longer screening intervals. The extent of long-term protec-
tion against high-grade lesions after a negative HPV DNA
test has been estimated to be longer than 5 years, but fur-
ther research is need to establish the most appropriate
screening interval (research need).
￿ HPV testing as a stand alone test is more effective than
cytology alone in identification of CIN2+ lesions in
women aged ≥ 35 years (I) and might be used as a primary
screening test in this age category. First follow-up results
from ongoing controlled randomized trials, which com-
pare longitudinal performance of Pap test vs. HPV testing
in screening programs, confirm the higher efficacy of HPV
screening that Pap screening (I). Local assessment is
needed before screening policies based on primary HPV
testing can be recommended (research need).
￿ In women aged < 35 years, HPV testing with immediate
referral to colposcopy leads to over diagnosis of CIN2+ as
compared with more conservative management strategies
(I). Thus, in women younger than 35 years of age with a
positive HPV test, cytology triage or repeat HPV testing at
12 months could be appropriate management strategies
to avoid over diagnosis and over treatment of CIN2+, but
this hypothesis needs confirmation in longitudinal stud-
ies (research need).
New molecular tests for management of women 
with HPV infection
Due to the relatively low specificity of HPV-DNA testing
and the high rate of false negative results at Pap test, new
molecular tests have been proposed in order to identify
women with a higher risk of progression to invasive can-
cer. These tests include (i) detection of type-specific HPV
persistence; (ii) detection of high-risk HPV E6/E7 mRNAs;
(iii) HPV genotyping to detect HPV-16 and HPV-18,
which have been associated with a higher risk of CIN2,3
or invasive cancer; (iv) measurement of high-risk HPV
load; (v) demonstration of high-risk HPV DNA integra-
tion; (vi) HPV subtyping by E6, L1, and LCR sequencing;
(vii) analysis of p16-INK4A expression. The implementa-
tion of these new molecular tests in cervical cancer screen-
ing could be useful to identify the subpopulation of high-
risk HPV-positive women who deserve a closer follow-up
and appropriate treatment.
Demonstration of HPV persistence
In women younger than 25 years of age, 20% of high-risk
HPV infections persist, whereas the risk of persistent infec-
tion is over 50% in women older than 55 years [18]. Only
a few women with HPV infection will develop cancer.
Thus, a single positive HPV test in the absence of clinically
significant lesions does not justify treatment [87]. Several
longitudinal studies demonstrated that persistence of
high-risk HPV is necessary for cancer initiation and pro-
gression and that the majority of high-risk HPV infections
and associated low-grade lesions spontaneously regress
within 6–18 months [1,88-93]. Screening strategies based
on repeat HPV testing at 12 months following detection of
a high-risk HPV could be useful to identify women at risk
of cancer, who should undergo colposcopy, and to avoid
overtreatment of lesions which will regress [94,95].
From a practical point of view, persistence can be defined
as the detection of the same HPV type (or, with a higher
degree of certainty, the same intratypic variant) two or
more times over a certain period. There is no consensus as
to the length of time that implies persistence, but at least
6 months to 1 year is the time frame that is usually chosen
[1]. A prospective study of type-specific HPV natural his-
tory, with a median follow-up of 5.1 years, showed partic-
ularly pronounced persistence of HPV-16 and markedly
increased risk of CIN3+ occurrence when HPV-16 per-
sisted, compared with any other HPV type [96]. Evalua-
tion of type-specific HPV persistence was used as a
management strategy for women with a positive HPV test
but normal Pap test in a controlled randomized trial in
Sweden, as above reported [84].
Analysis of high-risk HPV E6/E7 mRNA
Cervical cancer is characterized by overexpression of E6/
E7 mRNA of high-risk HPVs. A multiplex nucleic acidInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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sequence based amplification system (NASBA) assay was
developed for the identification of E6/E7 mRNA from
HPV types 16, 18, 31, 33, and 45 (PreTect™ HPV Proofer
kit, NorChip AS, Norway; now also distributed as Nucli-
SENS EasyQ®  HPV by bioMérieux SA, Marcy l'Etoile,
France). Analysis of E6/E7 mRNA expression with the Pre-
Tect™ HPV Proofer kit in 204 histologically confirmed
invasive cervical squamous cell carcinomas from Norwe-
gian women demonstrated the presence of oncogenic
transcripts of HPV-16, HPV-18, HPV-31, HPV-33, and
HPV-45 in 97% of HPV-positive cases, thus confirming
the expression of oncogenic E6/E7 in most invasive can-
cers and the involvement of the above HPV types in most
cases [97]. A cross-sectional study was performed in 4,136
women >30 years of age to compare the performance of
HPV E6/E7 mRNA detection with detection of HPV-DNA
by Gp5+/6+ consensus PCR [98]. No significant differ-
ence in sensitivity and specificity was observed between
the two tests for detection of HPV in high-grade squamous
intraepithelial lesion (HSIL). On the contrary, only a
small proportion of the HPV DNA-positive women with a
normal, ASC-US, or LSIL diagnosis had a detectable E6/E7
mRNA expression [98]. A comparative study between
HPV testing with Gp5+/6+ consensus PCR and high-risk
HPV E6/E7 mRNA testing with the PreTect™ HPV Proofer
kit showed the latest test had equal sensitivity and signifi-
cantly higher specificity for CIN2+ than PCR [99]. Moreo-
ver, E6/E7 mRNA-positive women had a significantly
higher risk to have a CIN2+ within 2 years than negative
women [99]. Interestingly, quantitative analysis of E6/E7
mRNA in cervical cancers, but not HPV DNA load, corre-
lated with patient survival [100]. The APTIMA HPV® Assay,
developed by Gen-Probe Incorporation (San Diego, CA),
employs transcription-mediated amplification and target
capture to detect HPV E6/E7 mRNA from 14 high-risk
HPV types, but it does not differentiate among the 14
high-risk types. Preliminary results obtained with this
assay suggest it has higher sensitivity and specificity than
HPV testing for identification of CIN2+ lesions [101].
Measurement of viral load
As above reported, higher cut-off values improve the spe-
cificity of the HC2 test [80-82] and correlate with an
increased risk of HPV persistence and development of
high-grade cervical lesions [78]. A more accurate quantifi-
cation of viral load can be achieved by using real-time
PCR to detect specific HPV types. This method allowed
demonstrating that high HPV-16 DNA load is associated
with CIN3 and invasive cervical carcinoma or with an
increased risk to develop CIN2–3 during follow-up
[92,102-106]. Thus, measurement of HPV-16 load by
real-time quantitative PCR has been proposed as a marker
of risk for CIN progression. Contrasting results have been
obtained with other high-risk HPV types, although, gener-
ally, a positive relationship between viral load and sever-
ity of cervical lesions has been reported [107-109].
HPV typing and subtyping
Women with HPV-16 and HPV-18 infection have a higher
probability to develop cancer than women with infection
by other high-risk HPV types [110-113]. Some studies
demonstrated that detection of HPV-16 and HPV-18 types
represents a risk factor for CIN2–3 [111,112], but also
identification of other high-risk HPV types could be useful
to select at risk patients [114,115]. Investigation of intra-
typic variants of HPV, which are defined by a difference in
the L1 gene sequence less than 2% of the reference HPV
prototype, have been proven to be useful in epidemiolog-
ical studies. In multiethnic populations, Asiatic-American
and other non-European variants of HPV-16 and HPV-18
are associated with a higher risk of persistent infection and
development of cervical precancerous lesions and inva-
sive cancer [116-118].
Investigation of high-risk HPV E6 e E7 variants also gave
interesting results. The T350G sequence variant of the
HPV16 E6 gene is associated with increased viral persist-
ence and oncogenicity [119,120]. The aminoacid change
caused by this mutation could affect E6 degradation activ-
ity on p53, besides changing its immunogenicity. Moreo-
ver, the L83V mutation of HPV16 E6 increases activation
of the MAPK pathway and cooperates with Notch 1 in
tumorigenesis [121]. HPV-16 sequence variants may also
be associated with different oncogenic potential, even in
the absence of virus integration, due to derepression of the
E6 and E7 promoter [122,123]. Thus, typing, subtyping,
and sequencing of HPV oncogenes and the upstream reg-
ulatory region could be useful for epidemiological pur-
poses but also as prognostic markers.
Number of HPV types included in HPV tests
Demonstration that some new HPV types, defined as
intermediate-risk, such as HPV-26, 53, 66, 73, and 82,
may be associated with the risk of cervical cancer has sug-
gested to extend the number of HPV types included in
HPV DNA tests. To assess the clinical impact of such an
extended test, the results from two randomized trials
which used HPV test for cervical cancer screening and
ASC-US triage, respectively, were analyzed [124]. In the
cancer screening protocol, addition of other high-risk
HPV types, besides the 12 most common, did not amelio-
rate test sensitivity. Likewise, when HPV testing was used
for ASC-US triage, test sensitivity was the greatest with 17
genotypes, but specificity was very low [124]. Thus, at the
moment, increasing the number of high-risk HPV types,
besides those already present in the FDA-approved HC2
test, does not seem to be advantageous neither for screen-
ing nor for triage of an abnormal Pap smear. On the other
hand, reduction of the number of high-risk types includedInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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in the HPV test to those most common in invasive cervical
cancer (e.g., HPV-16, HPV-31, HPV-33, etc.) could
improve HPV test specificity [125].
Analysis of HPV DNA integration
Integration of HPV-16 and other high-risk HPVs into the
genome of infected cells is an important step in tumori-
genesis, since it promotes expression of E6/E7 oncogenes.
Clinical studies demonstrated HPV DNA integration is
associated with a higher risk of treatment failure and with
a shorter disease-free interval than cases without integra-
tion [126,127]. Thus, assessment of HPV genome integra-
tion, by Southern-blot or quantitative real-time PCR
analysis of E2/E6 ratio, could represent a good prognostic
marker.
Analysis of p16-INK4A expression
In high-risk HPV infection, E7 binds to and degrades RB
which results in substantial up regulation of p16-INK4A
synthesis. In spite of the high level of p16-INK4A synthe-
sis, this protein remains functionally inactive, as E7
induces cyclin A and cyclin E expression, thereby func-
tionally bypassing its interference with the cell cycle. Anti-
bodies that are directed against p16-INK4A allow selective
staining of high-risk HPV-infected histological sections or
of cytological smears, but not other cervical epithelia, sug-
gesting that detection of this marker could provide diag-
nostic support to distinguish true CIN/dysplasia from
immature metaplasia or other non-neoplastic changes of
the cervix [128-131] and to improve interpretation of his-
tology [132]. Sensitivity and specificity for CIN2+ of p16-
INK4A overexpression testing by immunostaining in cer-
vical cell samples from HPV-DNA-positive women were
estimated in a nested sub-study of the NTCC trial [133].
This study demonstrated that HPV testing with p16-
INK4A triage improves test specificity for CIN2+. In fact,
p16-INK4A triage allows maintaining all the gain in sen-
sitivity obtained by HPV testing alone with respect to con-
ventional cytology, but with referral to colposcopy similar
to that of conventional cytology [133].
Analysis of immune response against HPV
Both antibody-mediated and cell-mediated immune
responses are essential for clearance of HPV and HPV-
related cervical lesions. The immune response against
HPV (and HPV virus-like particles, VLPs) is mainly directed
against type-specific immunodominant conformational
epitopes, although cross-reactivity has been documented,
such as between HPV-6 and HPV-11, HPV-31 and HPV-
33, HPV-18 and HPV-45. Serum levels of anti-HPV anti-
bodies are stable, even after virus clearance, so HPV sero-
logical assays simply demonstrate previous exposure to
the virus. Sensitivity of HPV serology is low (50–60%)
while specificity is high (about 90%). The low sensitivity
of the test is in part explained by lack of seroconversion in
some individuals with documented HPV infection [134].
On the other hand, high anti-HPV antibody titre is more
common in women with persistent infection than in
those who clear infection [134-136]. Moreover, seroposi-
tivity for different high-risk HPV types is associated with
high-grade CIN [137]. Unfortunately, no standardized
and validated HPV serological assays are available
[138,139].
Cell-mediated immune response is important for HPV
clearance, as suggested by the high incidence of persistent
HPV infection in AIDS or transplanted patients. Persistent
infection and cancer progression is also associated with
abnormal response of CD4+ T cells [140] and CD8+ T
cells [141].
Evidence synthesis on the use of new tests for diagnosis of HPV 
infection
￿ Most high-risk HPV infections recover spontaneously
within 6–12 months (I); persistent high-risk HPV infec-
tion and high-risk HPV E6/E7 expression are necessary
events for cervical cancer development and represent risk
factors for cervical cancer (I).
￿ HPV typing and subtyping provides epidemiological
data on HPV distribution and diffusion (II).
￿ In epidemiological surveys, type-specific HPV detection
could contribute to the evaluation of anti-HPV vaccine
efficacy (III).
￿ High HPV DNA load is a risk factor for cervical cancer
(II).
￿ HPV testing with p16-INK4A triage improves test specif-
icity for CIN2+ (II).
￿ Detection of anti-HPV antibodies demonstrates previ-
ous HPV exposure, but this test has low sensitivity (II); a
high antibody titre might indicate persistent infection (II).
￿ Patients with invasive cervical carcinoma have a defi-
cient HPV-specific cell-mediated immune response (II).
Recommendations on the use of new tests for diagnosis of HPV 
infection
￿ In order to demonstrate HPV persistence, repeat HPV
testing should be done at intervals of at least 12 months
(IA).
￿ HPV typing and subtyping in women with a normal or
dubious Pap test is useful since it allows to document per-
sistent infection by the same oncogenic HPV type (II) and
to demonstrate the presence of HPV-16 and HPV-18 DNA
which are markers of increased risk for cervical cancer (II).Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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Women with persistent high-risk HPV infection or with
the presence of HPV-16 and HPV-18 DNA should be
referred to colposcopy (B).
￿ Measurement of HPV-16 and other high-risk HPV DNA
load could be employed for triage of women with dubious
Pap test or with a positive HPV test (B), but further
research is needed to identify appropriate management
strategies for women with high HPV load (research need).
￿ Detection of high-risk HPV E6/E7 mRNA could be
employed for triage of women with dubious Pap test or
with a positive HPV DNA test (IIB). Due to its high sensi-
tivity and specificity (II) HPV E6/E7 mRNA testing should
be investigated as a stand alone test in primary screening
for cervical cancer (research need).
￿ HPV typing and subtyping is useful for epidemiological
investigation of HPV distribution and diffusion (B).
￿ Detection of p16-INK4A expression could be used as
triage of HPV positive cases (B) and abnormal Pap smears
(B) and to confirm histological analysis of cervical biop-
sies (B).
￿ Further research is needed to develop standardized
methods to measure anti-HPV immune response
(research need).
￿ In epidemiological surveys, evaluation of antibody-
mediated and cell-mediated anti-HPV immune response
can be used to assess immune response to anti-HPV vacci-
nation and to monitor duration of vaccine protection (B).
Prophylactic HPV virus-like particle vaccines
Two vaccines targeting HPV-16 and HPV-18, the types
that are responsible for 70% of invasive cervical cancers
[13,16], have been recently developed and experimented
for immunogenicity, safety, and efficacy in randomized
clinical trials. These vaccines are based on the self-assem-
bly of recombinant L1 protein into VLPs, that are non-
infectious capsids that contain no genetic material. They
were first developed and evaluated as monovalent vac-
cines targeting HPV-16 [142,143], thereafter as a bivalent
vaccine targeting HPV-16 and HPV-18 [144-146] and a
quadrivalent vaccine against low-risk HPV-6 and HPV-11,
besides HPV-16 and HPV-18 [147-149]. Intramuscular
injection of the vaccine induces high titres of neutralising
antibody in almost all subjects within a month from com-
pletion of the vaccination protocol [145,146,148-153].
Two HPV VLP vaccines have been developed and are avail-
able for primary vaccination in the European Union: an
AS04 adjuvanted L1 VLP vaccine against HPV-16 and
HPV-18 (Cervarix®, produced by GlaxoSmithKline),
which is administered i.m. in three doses (time 0, 1, and
6 months), and a quadrivalent alum adjuvanted L1 VLP
vaccine against HPV-16, HPV-18, HPV-6, and HPV-11
(produced by Merck & Co., Inc.; distributed in Europe by
Sanofi Pasteur MSD as Gardasil® and by Merck Sharp &
Dohme as Silgard®), which is administered i.m. in three
doses (time 0, 2, and 6 months). The bivalent vaccine is
advised for reduction of precancerous cervical lesions and
cancer incidence. The quadrivalent vaccine, besides cervi-
cal lesions, is advised for reduction of vulvar precancerous
lesions and genital condylomas.
The USA and several other Countries are targeting 11–12-
year-old girls for vaccination. In particular, the Italian
HPV vaccination program is universally offered free-of-
charge to all 12-year old girls, and advised to all adoles-
cent women before sexual debut. The choice of a target
population of young girls is based on the results of immu-
nogenicity and safety studies, which were conducted in
girls and boys aged 9–15 years (quadrivalent vaccine) and
aged 10–14 years (bivalent vaccine). These studies dem-
onstrated that both vaccines are safe and immunogenic,
and induce antibody titre which is more than 50 times the
titres induced by natural infection [145,146,150-156].
Efficacy of HPV VLP vaccines
Evaluation of vaccine efficacy in phase II-III clinical trials
was based on the demonstration of reduction of the inci-
dence of persistent HPV infection (two positive detections
at 4–6 months intervals) and on reduction of the inci-
dence of precancerous lesions (CIN2 and CIN3) caused
by HPV vaccine types. International standards for treat-
ment of CIN2/3 are ablative therapy. Moreover, in pro-
spective studies, it is not ethical to allow a woman to
develop invasive disease in order to demonstrate efficacy
of prevention strategies. In this regard, WHO and other
international agencies indicated CIN2/3 as clinical end-
point surrogate to demonstrate efficacy of cancer preven-
tion.
Randomised clinical trials demonstrated that three doses
vaccination is effective for the prevention of persistent
infection and for precancerous lesions caused by HPV
genotypes included in the vaccine. Results on efficacy
reported in published studies are mainly two types: (i) per
protocol analysis, which demonstrates the pure efficacy of
the vaccine, obtained by analysis, in the experimentation
context, of clinical data of women who did not violate the
protocol (woman who received three doses of vaccine or
placebo as expected), who resulted negative for all HPV
genotypes included in the vaccine both at enrolment or
during the administration of the vaccine. (ii) modified
intention to treat analysis, where evaluation of efficacy is
more similar to the clinical setting in the general popula-
tion, since it includes all enrolled women, as long as theyInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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receive at least the first dose of vaccine or placebo and
who resulted negative for all HPV genotypes of the vaccine
merely at the time of administration of first vaccine dose.
Efficacy of the quadrivalent HPV VLP vaccine
A phase II randomised trial was carried out on 552
women (277 randomised in the vaccine group and 275 in
the placebo group). Per protocol efficacy analysis demon-
strated that Gardasil® reduced by 90% (95% CI, 71–97%)
the incidence of persistent infection and genital lesion
associated with the HPV genotypes included in the vac-
cine [147]. A subset of subjects participated to a subse-
quent follow-up of this study. Following five years from
enrolment, efficacy on combined incidence of persistent
infection of HPV-6/11/16/18-related disease was 96%
(95% CI 83.8–99.5%) [143]. Modified intention to treat
analysis demonstrated that vaccination reduced incident
infections and cervical lesions by 94% (95% CI, 83–
98.3%) [152].
Phase III efficacy studies of the quadrivalent vaccine
Gardasil® were conducted in the context of the two proto-
cols Females United to Unilaterally Reduce Endo/Ectocer-
vical Disease (FUTURE) I and FUTURE II:
- FUTURE II trial. Per protocol analysis in over 10,000
women (5,305 randomised in the vaccination group and
5,260 randomised in the placebo group) aged 15–26
years demonstrated that, a after a mean 3 year follow-up
period, vaccine efficacy was 98% (95% CI, 86–100%) for
prevention of CIN2,3 and in situ adenocarcimoma associ-
ated with HPV-16 and HPV-18 [148]. It is to notice that
the unique woman, included in the vaccine group, who
developed a HPV-16 or HPV-18 associated lesion, had a
positive CIN3 for HPV-52 at the initial control and in all
the following 5 samplings during follow-up, only one
these samples resulted to be HPV-16 positive. Modified
intention to treat analysis (definedalso unrestricted suscepti-
ble population) in randomised women (95% of the study
population), who were negative for the vaccine types at
the first dose administration, and who did not strictly
adhere to the study protocol, demonstrated vaccine effi-
cacy was 95% (95% CI, 85–99%). Intention to treat analy-
sis including all randomised subjects, without any pre-
vaccine screening, was used to predict efficacy of vaccina-
tion on incident/prevalent HPV infections and related
lesions in the general population, who demonstrated an
impact of 44% (95% CI 26–58%) at 3 years follow-up.
- FUTURE I trial. Per protocol analysis on over 5,000
women (2,261 randomised in the vaccination group and
2,279 randomised in the placebo group) aged between 16
and 24 years showed that after an average period of 3 years
since vaccine administration, the vaccine had 100% effi-
cacy (95% CI 94–100%) for prevention of condylomas,
vaginal and vulvar intraepithelial neoplasia related to
HPV-6/11/16/18 and 100% efficacy (95% CI 94–100%)
for prevention of CIN1–3 or in situ adenocarcinoma asso-
ciated with vaccine HPV genotypes [149]. Modified inten-
tion-to-treat analysis (also defined unrestricted susceptible
population) showed 95% efficacy (95% CI 87–99%)
regarding precancerous genital lesions, vulvar or vaginal,
or condylomas and 98% efficacy (95% CI 92–100%) for
CIN1+ or in situ adenocarcinoma caused by vaccine HPV
types. The intention-to-treat analysis showed a 73% efficacy
(95% CI, 58–83%) in preventing external anogenital or
vaginal lesions of any degree and a 55% efficacy (95% CI,
40–66%) in preventing incident and prevalent cervical
lesions of any grade associated with vaccine HPV geno-
types, at 3 years follow up. In both FUTURE I and II stud-
ies, vaccination did not appear to significantly alter the
course of infection or lesions due to HPV which were
already present before the first dose of vaccine.
- Per-protocol efficacy analysis of the results achieved by the
combination of three randomized clinical trials of vacci-
nation (n = 7,811) versus placebo (n = 7,785) showed
that vaccination, after an average follow-up period of 3
years, has an efficacy of 100% (95% CI 72–100%) in pre-
venting vulvar and vaginal lesions grade 2 and 3 associ-
ated with HPV-16 and HPV-18. Modified intention-to-treat
analysis demonstrated an efficacy of 97% (95% CI 79–
100%) and intention-to-treat analysis, on a total of 18,174
randomised women, showed an efficacy of the vaccine at
three years of 71% (95% CI, 37–88) in the prevention of
incident/prevalent HPV-associated lesions [153].
- Per-protocol efficacy analysis of the results achieved by the
combination of four randomized clinical trials of vaccina-
tion with the quadrivalent vaccine (n = 9,087) and its
HPV-16 L1 component (n = 1,204) vs. placebo (n =
10,292) showed that, after a follow-up of 3 years, in HPV-
16 and HPV-18 negative women, vaccine efficacy was
99% (95% CI 93–100) in preventing development of
CIN2/3, in situ adenocarcinoma or invasive cervical cancer
associated with HPV-16 and HPV-18. Efficacy was 98%,
(95% CI 93–100) in the population of modified intention-
to-treat analysis. The modified intention-to-treat analysis dem-
onstrated an impact of the vaccine of 44% (95% CI, 31–
55) in reducing the incidence of cervical lesions associated
with HPV-16 and HPV-18, in the case of HPV type vaccine
diseases already prevalent/incident in the population
[157].
Efficacy of the AS04 adjuvanted bivalent VLP vaccine
Efficacy the AS04 adjuvanted bivalent VLP vaccine has
been assessed in phase II-III studies. A pilot randomized
phase II study on safety, immunogenicity, and efficacy of
the vaccine for prevention of incident and persistent HPV-
16 and HPV-18 infection enrolled and randomized 1,113Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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women aged 15–25 years to receive either the vaccine or
placebo [144]. Study participants were initially seronega-
tive for HPV-16 and HPV-18 by ELISA and negative for
HPV-16 and HPV-18 DNA by PCR and had negative
results at cervical cytology. In the per protocol analysis, vac-
cine efficacy was 91.6% (95% CI, 64.5%–98.0%) against
incident infection and 100% against persistent infection
(95% CI, 47%–100%) with HPV-16/18 at 18 months
post-vaccination. In the intention-to-treat analyses, vaccine
efficacy was 95.1% (95% CI, 63.5%–99.3%) against per-
sistent cervical infection with HPV-16/18 and 92.9%
(95% CI, 70%–98.3%) against cytological abnormalities
associated with HPV-16/18 infection. In a subsequent
report from the same study, after a follow-up of 4–5 years,
per protocol analysis on the results obtained from a group
of 732 women (367 in the vaccination group and 365 in
the placebo group) who received all three doses of vac-
cine, demonstrated vaccine efficacy against incident infec-
tion was 96.9% (95% CI, 81.3%–99.9%) and 100%
(33.6%–100%) against persistent infection for 12 months
[145]. Efficacy against CIN lesions associated with
HPV16/18 infection was 100% (95% CI, 42.4%–100%),
since 8 cases of CIN1/2 occurred in the placebo group and
none in the vaccination group. Interim results at a mean
follow-up of 14.8 months (SD 4.9) from a large, interna-
tional phase III study have been published [149]. In this
trial, 18525 women aged 15–25 years from North Ameri-
can, South American, European, Asian, and Australian
countries were randomly assigned to receive either
HPV16/18 vaccine (n = 9,258) or hepatitis A vaccine (n =
9,267) at 0, 1, and 6 months. Two cases of CIN2+ associ-
ated with HPV16 or HPV18 DNA were seen in the HPV16/
18 vaccine group; 21 were recorded in the control group.
Based on these data, vaccine efficacy against CIN2+ con-
taining HPV16/18 DNA was estimated to be 90.4%
(97.9% CI, 53.4–99.3), but, a post hoc analysis demon-
strated that the HPV16 or HPV18 DNA in the 2 CIN2+
cases in the vaccination group and in 1 case of the control
group were already present at study entry. Efficacy against
12-month persistent HPV-16/18 infection was 75.9%
(97.9% CI, 47.7–90.2).
Efficacy of HPV VLP vaccination in HPV-positive women
In women positive for HPV DNA, HPV VLP vaccination
does not accelerate clearance of the virus nor prevents
incident CIN2+ caused by HPV vaccine types. This finding
has been demonstrated in a randomized phase III trial in
2189 women aged 18–25 years, who received the AS04
adjuvanted bivalent VLP vaccine [158] and in two rand-
omized trials of the quadrivalent HPV vaccine enrolling
17,622 women without consideration of HPV status
[159].
Cross-protection against oncogenic HPVs
Two clinical trials have evaluated the efficacy of Cervarix™
on other oncogenic types [144-146]. They demonstrated
vaccination led to sustained cross-protection against inci-
dent infection with HPV-45 and -31 for the entire follow-
up period up to 5.5 years and cross-protection against six-
month persistent infection due to HPV-45, -31 and -52
[160]. Furthermore, broad protection was observed
against 12-month persistent infections (defined as detec-
tion of the same HPV type in all available cytology sam-
ples collected over any 12-month period) with 12
combined oncogenic HPV types, not including HPV-16
and -18 (vaccine efficacy 27.1%; 97.9% CI: 0.5–46.8)
[160]. The impact of Gardasil® HPV quadrivalent vaccine
on the rates of infection and disease associated with 10
HPV types not included in the vaccine was estimated in a
population of women that was, pre-vaccination, seroneg-
ative and PCR-negative to all HPV types for which testing
was available and had a normal Pap test [161]. Within
approximately 3 years of follow-up, combined efficacy for
CIN2/3 or adenocarcinoma in situ caused by all 10 non-
vaccine HPV types was 38% (95% CI:6–60). The final
end-of study data with approximately 3.6 years follow-up
showed similar high vaccine efficacy [161].
Side effects of prophylactic HPV VLP vaccines
Data on safety of the quadrivalent HPV VLP vaccine
reported a higher rate of side effects in the vaccination
group than in the placebo group. Side effects included
local reaction at the site of injection (erythema, pain,
edema) (altogether, 86.8% in the vaccine group vs. 77.4%
in the placebo group, respectively) and systemic side
effects, such as fever (13.5% vs. 10.2%, respectively)
[149]. Also data on safety of the bivalent vaccine reported
a higher rate of injection site symptoms and systemic side
effects (fatigue, headache, myalgia) in the vaccine group
than in the control group [146]. No increased incidence of
spontaneous abortion, late fetal deaths, or congenital
anomalies was observed in pregnancies occurring in
women receiving either type of vaccines as compared with
controls [146,148].
Recommendations on the use of prophylactic HPV vaccines
￿ HPV vaccination with the quadrivalent vaccine is safe
and efficacious for the prevention of incident high-grade
precancerous lesions, in situ adenocarcinoma, invasive
cervical cancer, high-grade vulvar and vaginal lesions, and
genital warts correlated with HPV-16, HPV -18, HPV -6,
and HPV -11 (I).
￿ HPV vaccination with the AS04 adjuvanted bivalent vac-
cine is safe and efficacious for the prevention of incident
and persistent HPV-16 e HPV-18 infection and CIN1+ cor-
related with HPV vaccine types (I)Infectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
Page 16 of 22
(page number not for citation purposes)
￿ Long-term efficacy (> 5 years) of HPV vaccination is cur-
rently under investigation (research need).
￿ Efficacy of HPV vaccination has been demonstrated in
women aged 15–26 years, who had not been previously
exposed to HPV vaccine types (I); results on efficacy in
women older than 26 years are not available yet (research
need).
￿ Results on immunogenicity and safety (but not efficacy)
justify vaccination in girls aged 9–14 years (II).
￿ Efficacy of HPV vaccination in males is currently under
investigation (research need).
￿ HPV vaccination in males is not considered to be cost-
effective (III).
￿ HPV vaccination should be done before exposure to
genital HPV, since it lacks efficacy in women who have
already been infected (IA), and it does not enhance virus
clearance (IA).
￿ Screening for cervical cancer should be recommended
both in vaccinated and non-vaccinated women according
to current guidelines (II). Screening protocols could be
modified only after appropriate clinical trials (research
need).
￿ Further research is needed to assess the duration of vac-
cine protection, variations in the prevalence of HPV types
in vaccinated women and in the general population, and
surveillance of side-effects of vaccination (research need).
Summary of recommendations and guidelines
When should HPV testing be used in cervical-cancer 
screening programs?
￿ in ASCUS triage (IA).
￿ in the follow-up after treatment of CIN2/3 (IA).
￿ as a screening test for cervical cancer, as an alternative to
cytology, in women older than 30 years, with cytology or
repeat HPV testing as triage tests (IA).
Efficacy in cervical cancer screening has been proven for
both PCR-based and signal amplification-based HPV tests
(I).
What is the role of new HPV tests in the diagnosis of HPV 
infection?
￿ Evaluation of HPV persistence may be useful to identify
patients at risk for cervical cancer, who should be referred
for colposcopy (A).
￿ HPV typing and subtyping can be used for epidemiolog-
ical evaluation of HPV distribution and diffusion (B), for
identification of persistent infection (B), for identification
of HPV-16 and HPV-18, which are associated with a
higher risk of precancerous lesions (B) or invasive cervical
cancer (B), and for monitoring the efficacy of vaccination
(A). But, there is insufficient evidence to define the best
protocol to manage women with positive tests (I).
￿ Detection of high-risk HPV E6/E7 mRNA may be useful
to identify women at risk for cervical cancer and with
worse prognosis (IIB). Further research is needed to define
the best protocol to manage women with a positive test
and to evaluate test efficacy in primary screening pro-
grams.
￿ Measurement of HPV-16 DNA load in women with nor-
mal cytology may be useful to identify women at risk for
cervical cancer (IIB). But, there is insufficient evidence to
define the best protocol to manage women with positive
tests (I).
￿ In epidemiological surveys, HPV serological testing and
measurement of anti-HPV cellular immune response
could be useful to monitor the duration of vaccine protec-
tion (B).
Who should be vaccinated and how should vaccine efficacy 
be evaluated?
￿ Quadrivalent HPV VLP vaccine is safe and effective in
the prevention of cervical and vulvar precancerous
lesions, in situ adenocarcinoma, invasive cervical cancer
and genital warts associated with vaccine HPV types in
women aged 15–26 yrs (I).
￿ HPV vaccination with the AS04 adjuvanted bivalent vac-
cine is safe and efficacious for the prevention of incident
and persistent HPV-16 e HPV-18 infection and CIN1+ cor-
related with HPV vaccine types in women aged 15–26 yrs
(I)
￿ HPV vaccine should be administered before genital HPV
exposure, since the benefit of vaccination declines in
women already positive for HPV DNA (IA).
￿ In epidemiological surveys, HPV serological testing and
HPV genotyping could be useful to monitor vaccine effi-
cacy (research need).
￿ Cervical cancer screening is recommended both in vac-
cinated and non-vaccinated women, in agreement with
current guidelines for cervical cancer prevention (III).
￿ Further research is needed to assess the duration of vac-
cine protection, variations in the prevalence of HPV typesInfectious Agents and Cancer 2008, 3:14 http://www.infectagentscancer.com/content/3/1/14
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in vaccinated women and in the general population, and
surveillance on side-effects of vaccination (research need).
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